Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial

M Kaufmann; E Bajetta; L Y Dirix; L E Fein; S E Jones; J Cervek; C Fowst; A Polli; E Di Salle; G Massimini; G Piscitelli

doi:10.1016/s0959-8049(00)00240-9

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial

Eur J Cancer. 2000 Sep:36 Suppl 4:S86-7. doi: 10.1016/s0959-8049(00)00240-9.

Authors

M Kaufmann¹, E Bajetta, L Y Dirix, L E Fein, S E Jones, J Cervek, C Fowst, A Polli, E Di Salle, G Massimini, G Piscitelli

Affiliation

¹ Universitätsklinik, Goethe-Universität, 60596, Frankfurt, Germany. m.kaufmann@em.uni-frankfurt.de

PMID: 11056333
DOI: 10.1016/s0959-8049(00)00240-9

Abstract

Exemestane is an aromatase inactivator. 769 Postmenopausal women with advanced breast cancer who had failed on tamoxifen were randomised to exemestane or megoestrol acetate in this double-blind trial. Objective response rate was similar between treatments. Median time to progression, time to treatment failure and overall survival was significantly longer with exemestane. Drug-related withdrawals and drug-related deaths were more common with megoestrol acetate.

Publication types

Clinical Trial
Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Androstadienes / therapeutic use*
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Double-Blind Method
Enzyme Inhibitors / therapeutic use
Female
Humans
Megestrol Acetate / therapeutic use*
Postmenopause*
Survival Analysis
Tamoxifen / therapeutic use*
Treatment Failure

Substances

Androstadienes
Antineoplastic Agents
Enzyme Inhibitors
Tamoxifen
exemestane
Megestrol Acetate